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Abstract
Background Real-world data of disease prevalence represents an important but underutilised source of evidence for health 
economic modelling.
Aims The aim of this study was to estimate nationwide prevalence rates and summarise the characteristics of 199 chronic con-
ditions using Danish population-based health registers, to provide an off-the-shelf tool for decision makers and researchers.
Methods The study population comprised all Danish residents aged 16 years or above on 1 January 2013 (n = 4,555,439). 
The study was based on the linkage of national registers covering hospital contacts, contacts with primary care (including 
general practitioners) and filled-in out-of-hospital prescriptions.
Results A total of 65.6% had one or more chronic condition. The ten conditions with the highest degree of prevalence 
were hypertension (23.3%), respiratory allergy (18.5%), disorders of lipoprotein metabolism (14.3%), depression (10.0%), 
bronchitis (9.2%), asthma (7.9%), type 2 diabetes (5.3%), chronic obstructive lung disease (4.7%), osteoarthritis of the knee 
(3.9%) and finally osteoporosis (3.5%) and ulcers (3.5%) in joint tenth place. Characteristics by gender, age and national 
geographical differences were also presented.
Conclusions A nationwide catalogue of the prevalence rates and characteristics of patients with chronic conditions based 
on a nationwide population is provided. The prevalence rates of the 199 conditions provide important information on the 
burden of disease for use in healthcare planning, as well as for economic, aetiological and other research.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-019-0167-7) contains 
supplementary material, which is available to authorized users.
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Key Points for Decision Makers 
Real-world evidence of disease prevalence is important 
for estimating the burden of disease, cost of illness and 
budget impact of new health technologies.
The Danish civil registration number provides a unique 
opportunity to link different types of register data for an 
individual patient, thus providing the best possible infor-
mation on the actual treatment of chronic diseases.
Nationwide register-based prevalence statistics for 199 
chronic diseases show, for most disease areas, a higher 
current treatment level than that expected from epide-
miological research. In 2013, almost two-thirds of the 
entire Danish population aged 16 years or above either 
had a hospital diagnosis or had been in medical treat-
ment for one or more chronic condition.
1 Introduction
Worldwide, the financial pressures on healthcare providers 
are increasing. To control the rising cost of healthcare, deci-
sion makers need access to real-world evidence of current 
treatment patterns [1, 2]. Real-world evidence of disease 
prevalence is important for estimating the burden of disease, 
cost of illness, and budget impact of new health technologies 
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administration such as claims and management, surveillance 
and control functions [37]. The comprehensiveness, scope 
and population completeness are unique to Denmark and 
other Scandinavian countries, enabling individual linkage 
across registers by means of the individual personal identi-
fication number assigned to each person [38]. The main reg-
ister used was the Danish National Patient Register (NPR) 
[39], including the Danish Psychiatric Central Research 
Register [40], containing treating-physician-reported Inter-
national Statistical Classification of Diseases, 10th Revision 
(ICD-10) hospital diagnoses. Moreover, to ensure the inclu-
sion of patients not treated in hospitals, the National Health 
Service Register (NHSR) [41] and National Prescription 
Registry (TNPR) [42] were included in the study, since the 
NPR did not include diagnosis data from private specialist 
doctors or GPs. The NHSR contains data collected primar-
ily for administrative purposes from health contractors in 
primary healthcare. It includes information about citizens, 
providers and health services, but minimal clinical infor-
mation. Furthermore, the TNPR, comprising all prescribed 
and distributed medicines outside hospitals, was included 
to ensure the best possible identification of conditions and 
the representativeness thereof by clinical recommendation. 
All registers had a unique civil registration number for each 
person; furthermore, birth date, gender and other informa-
tion were derived from the Danish Civil Registration Sys-
tem [43]. The registers used are described in more detail in 
other studies [44, 45]. Table 1 summarises the details of the 
registers used.
2.3  The Definition of a ‘Chronic Condition’, Clinical 
Ratification and Review
A thorough description of the distinct phases and methods 
used are provided elsewhere [44–46]. In short, a ‘chronic 
condition’ was defined in line with previous studies, i.e. the 
‘condition had lasted or was expected to last twelve or more 
months and resulted in functional limitations and/or the need 
for functional limitations and/or the need for ongoing medi-
cal care’ [47–49]. An expert panel consisting of professors, 
medical specialists and other experts from Aalborg Univer-
sity, the Clinical Institute of Aalborg University at Aalborg 
University Hospital, the Department of Clinical Epidemiol-
ogy at Aarhus University Hospital, and others was consulted 
using the Delphi method in order to identify which of the 
approximately 22,000 ICD-10 codes and conditions could 
be considered ‘chronic’ based on the definition [44]. The 
ICD-10 codes were aggregated to 199 conditions, yet sev-
eral conditions included subgroups of ICD-10 codes; thus, 
some consequently contained multiple conditions within the 
same disease area. Subsequently, all ICD-10 conditions con-
sidered chronic by definition were included in the study in 
pursuit of comprising the full-population burden of chronic 
[3, 4]. In addition, it is important to obtain unbiased, inde-
pendent documentation of disease burden, as there may be 
concerns with the cost-of-illness studies funded by compa-
nies [5].
The burden of chronic diseases is increasing rapidly in 
most countries. In Denmark, approximately 30–50% of 
the adult population have one or more chronic condition 
or long-standing illness [6–10]. Moreover, the burdens of 
chronic conditions are increasing [11–20]. The numbers and 
expenditure are growing along with an ageing population, 
and up to 80% of total healthcare costs can be attributed to 
chronic conditions [21–24]. Thus, the need for reliable and 
affordable estimates of the prevalence and disease burden of 
chronic conditions to guide decision-making in healthcare 
is increasing [24–26].
There are different ways to measure the prevalence of 
chronic conditions, varying from community-based health 
surveys and screening investigations to register-based stud-
ies. The choice of definitions and methods naturally affects 
which patients are included and hence the prevalence [27, 
28].
The Scandinavian countries have an established tradition 
of documenting the diseases and hospital treatments of the 
entire population in registers; however, the registers have 
primarily been used to study individual conditions rather 
than to assess the total burden of chronic conditions [7, 24, 
26, 29–34], or to forecast drug spending to help with deci-
sion-making [35, 36].
The aim of the present study was to estimate the national 
prevalence rates and to summarise the characteristics of 199 
chronic conditions using the complete Danish population 
aged 16 and above. To the best of the authors’ knowledge, 
the current study is the most comprehensive, independent 
register-based attempt to estimate the full-population prev-
alence-based disease burden of chronic diseases.
2  Methods
2.1  Study Population
The nationwide study population and cohort consisted 
of 4,555,439 Danish residents who were alive and aged 
16 years or above on 1 January 2013, of which 49.2% were 
men.
2.2  The Registers
In Scandinavian countries, general practitioners (GPs) and 
hospitals have a long-standing tradition of reporting dis-
eases, treatments, medications and other treatment-related 
information. This is done at the micro level for national 
health registers. Register data are collected mostly for public 
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conditions. Consequently, the 199 conditions consisted of 
several ICD-10 codes and thus groups of illnesses.
2.4  Data Collection: The Basis of the Data 
Algorithms
Since many chronic conditions last longer than the defined 
12 months, but do not last for a lifetime, the varying ‘chro-
nicity’ of conditions was divided into four groups of severity 
[44]:
• Category I: stationary to progressive chronic conditions 
(no time limit equals inclusion time going back from the 
time of interest for as long as valid data were available. 
In the current study, this starting point was defined by the 
introduction of the ICD-10 diagnosis coding in Denmark, 
in 1994).
• Category II: stationary to diminishing chronic conditions 
(10 years from register inclusion time to the time of inter-
est).
• Category III: diminishing chronic conditions (5 years 
from register inclusion time to the time of interest).
• Category IV: borderline chronic conditions (2 years from 
register inclusion time to the time of interest).
The above four categories were designed to include the 
different chronic conditions when registers covered several 
years and still have the best possible clinical certainty that 
the conditions were still existing at the fixed time point of 
1 January 2013. All 199 chronic conditions were divided 
into one of the four categories by medical specialists and 
experts. An algorithm was created for data collection based 
on the four categories, as seen in Fig. 1 for all 199 conditions 
and coherent ICD-10 codes. However, 35 of the 199 chronic 
conditions were not considered by experts to be properly 
representative using solely NPR diagnosis data. Thus, they 
created more complex algorithms using several registers 
besides diagnosis data, ranging from medicine and hospi-
tal treatments to GP services. For example, medicine and 
coherent indication codes were used to identify people with 
depression without a hospital diagnosis, and only when the 
indication codes identified the medicine used for depression, 
and not others such as pain treatment, etc. The same applied 
to GP services indicating, for example, diabetes or chronic 
obstructive lung disease (COPD) treatment, etc., where no 
hospital diagnosis was found. The details of all 199 unique 
definitions, their categorisation into one of the four catego-
ries and algorithms for replication can be found elsewhere 
[44, 45].
2.5  Statistical Analysis
Prevalence estimates were calculated in both per cent and 
per 1000 subjects; the proportion was calculated as the num-
ber of conditions identified divided by the total number of 
residents aged 16 years or above alive on 1 January 2013 
(n =4,555,439) multiplied by either 100 or 1000. Thus, prev-
alence was calculated from a specific point in time, based 
on the above inclusion time periods back in time for each 
condition. See Fig. 1 or further details in the literature [44].
The prevalence proportions for all conditions were strati-
fied and presented by age and sex for use by, for example, 
local authorities, health planners and national researchers.
Direct standardisation of age, gender and education based 
on the national average (i.e. using Denmark as the standard/
reference population for age, gender and education) [50] 
was applied to illustrate differences free of basic socio-eco-
nomic effects (presented in brackets in Tables 2 and 3 and 
the electronic supplementary material). The gender and age 
(10-year intervals) variables were obtained from the Danish 
Civil Registration System [43], and the educational variables 
were obtained from the Population Education Register using 
Danish Education Nomenclature (DUN) classification [51].
Finally, tables were stratified geographically in the five 
national regions, and the mean age and standard deviation 
(SD) for each condition were calculated, but due to size and 
relevance for the international reader, geographical regions, 
mean age and SDs are presented in the electronic supple-
mentary material.
All data management and data analysis were performed 
in SAS 9.4 (from Statistics Denmark’s research servers).
Fig. 1  The four categories of chronicity and the inclusion time periods
Prevalence Rates of 199 Chronic Conditions
Table 2  Overview of disease prevalence in Denmark: number of patients, prevalence rate (per 1000), age and gender (per cent within gender) of 
disease groups of conditions and chosen medicine for Denmark at 1 January 2013
Name of condition ICD-10 code/definition Number and prevalence





75 + (per 
1000)N Per 1000 
(standardised)
Per cent
B—Viral hepatitis and human 
immunodeficiency virus (HIV) 
disease
B18, B20–B24 8813 1.9 (2.0) 65.3 1.8 2.4 0.3
C—Malignant neoplasms C00–C99; D32–D33; D35.2–
D35.4; D42–D44
229,331 50.3 (50.4) 43.3 10.2 69.4 155.8
D—In situ and benign neoplasms, 
and neoplasms of uncertain or 
unknown behaviour and diseases 
of the blood and blood-forming 
organs and certain disorders 
involving the immune mecha-
nism
D00–D09; D55–D59; D60–D67; 
D80–D89
116,560 25.6 (25.7) 36.3 13.2 27.3 80.1
E—Endocrine, nutritional and 
metabolic diseases
E00–E14; E20–E29; E31–35; 
E70–E78; E84–E85; E88–E89
877,433 192.6 (192.7) 45.6 43.5 279.6 501.4
G—Diseases of the nervous 
system
G00–G14; G20–G32; G35–G37; 
G40–47; G50–64; G70–73; 
G80–G83; G90–G99
561,054 123.2 (123.5) 40.1 70.6 162.2 188.6
H—Diseases of the eye and 
adnexa and diseases of the ear 
and mastoid process
H02–H06; H17–H18; H25–H28; 
H31–H32; H34–H36; H40–55; 
H57; H80, H810; H93, H90–
H93
448,176 98.4 (98.6) 47.5 25.6 112.6 394.4
I—Diseases of the circulatory 
system
I05–I06; I10–28; I30–33; 
I36–141; I44–I52; I60–I88; I90–
I94; I96–I99
1,254,427 275.4 (275.5) 45.3 73.3 381.5 753.9
J—Diseases of the respiratory 
system
J30.1; J40–J47; J60–J84; J95, 
J97–J99
1,210,598 265.7 (266.3) 42.1 209.3 298.8 381.9
K—Diseases of the digestive 
system
K25–K27; K40, K43, K50–52; 
K58–K59; K71–K77; K86–K87
329,337 72.3 (72.6) 44.7 41.3 86.3 157.4
L—Diseases of the skin and sub-
cutaneous tissue
L40 65,469 14.4 (14.5) 47.8 7.9 19.3 21.7
M—Diseases of the musculoskel-
etal system and connective tissue
M01–M25; M30–M36; M40–
M54; M60.1–M99
1,032,808 226.7 (227.1) 42.2 113.2 291.2 470.5
N—Diseases of the genitourinary 
system
N18 20,162 4.4 (4.5) 59.4 1.0 4.8 20.0
Q—Congenital malformations, 
deformations and chromosomal 
abnormalities
Q00–Q56; Q60–Q99 124,898 27.4 (27.5) 41.7 33.9 23.2 16.2
F—Mental and behavioural 
disorders
F00–99 683,194 150.0 (150.7) 41.0 135.2 150.2 223.7
Having one or more chronic 
condition
2,989,441 656.2 (657.2) 45.5 480.5 771.5 953.9
Mean number of chronic condi-
tions (std. dev)
2.2 (2.8) – – 2.0 (2.6) 1.1 (1.6) 2.7 (2.8) 5.3 (3.6)
 Depression  medicinec,** ATC: N06A 529,918 116.3 (116.7) 36.3 88.7 126.9 201.9
 Antipsychotic  medicinec,** ATC: N05A 138,625 30.4 (30.6) 45.7 26.1 31.9 44.8
 Indication prescribed anxiety 
 medicinec,**
All prescriptions with either indi-
cation code 163 (for anxiety) or 
371 (for anxiety, addictive)
102,568 22.5 (22.6) 34.5 19.9 23.7 30.1
 Heart failure  medicationc,** ATC: C01AA05, C03, C07 or 
C09A with indication code 430 
(for heart failure)
7468 1.6 (1.7) 64.6 0.1 2.0 7.5
 Ischaemic heart  medicationc,** ATC: C01A, C01B, C01D, C01E 129,484 28.4 (28.5) 51.8 1.4 32.0 147.3
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3  Results
3.1  The Prevalence Rates
The population’s full burden of chronic disease, with all the 
chronic conditions summarised, was 65.6% (see Table 2 or 
Table 3). The ten most prevalent conditions were hyper-
tension (23.3%), respiratory allergy (18.5%), disorders of 
lipoprotein metabolism (14.3%), depression (10.0%), bron-
chitis (9.2%), asthma (7.9%), type 2 diabetes (5.3%), COPD 
(4.7%), osteoarthritis of the knee (3.9%) and osteoporosis 
(3.5%)/ulcer (3.5%); see the overview of conditions solely 
by overall disease groups in Table 2 and all 199 conditions 
in Table 3. 
In general, prevalence naturally increases with increasing 
age across most conditions (see also Supplementary Mate-
rial 2 and 6 with 10-year age intervals). Moreover, patients 
are relatively older within cancers and endocrine, nutritional 
and metabolic diseases and diseases of the circulatory sys-
tem, the eye and adnexa, the ear and mastoid process, and 
the musculoskeletal system and connective tissue compared 
to within other conditions. A relatively younger patient 
population is seen within diseases of the respiratory system 
(especially allergies and asthma) and mental- and behav-
ioural disorders. Mental disorders actually show a decrease 
in prevalence in later life. The conditions with the youngest 
population are, for example, seen within human immunode-
ficiency virus (HIV) and hepatitis.
Gender differences are seen across conditions, where 
women are overrepresented within most conditions—except, 
for example, heart failure and ischaemic heart diseases, 
stroke, some cancers, diabetes, disturbances in lipopro-
tein circulation and other lipids, inguinal hernia, hearing 
loss such as tinnitus, chronic renal failure, sleep disorders, 
schizophrenia, attention deficit/hyperactivity disorder 
(ADHD), mental and behavioural disorders due to the use 
of alcohol, and others. Coherently, women are treated more 
often than men with medication, except for ischaemic heart 
medications.
Some further characteristics and differences between 
conditions are seen and described in Supplementary Mate-
rial 1–6. This includes geographic regional tables, further 
age characteristics with mean age and SD, more age inter-
vals, further comments on common selected conditions and 
regional differences, etc.
4  Discussion
Based on the present findings, almost two-thirds of the 
entire Danish population aged 16 years or above have one 
or more chronic condition. Seen in the context of previous 
studies, this is around 10–20 percentage points higher than 
several other Danish studies [6, 7] as well as international 
studies [27, 28]. The overall estimates are also twice the 
official estimates of the Danish National Board of Health 
[8]. However, both national and international comparisons 
are difficult due to differences in methodology and data pos-
sibilities, so estimates should be compared with caution. 
For example, some American studies report that about 50% 
of the US population has a chronic condition [52, 53], but 
reliable overall estimates are difficult to obtain as to why 
improvement has been recommended [17]. Furthermore, as 
the US often has higher disease prevalence than the EU—
often differing by 20–100% across different conditions [54] 
—the present study suggests that the US estimates might 
be even higher.
4.1  Strengths and Limitations
The strength of this study is the detailed, full nationwide 
register-based collection and categorisation of all data on 
actual chronic conditions and treatments for Danes in public 
Table 2  (continued)
Name of condition ICD-10 code/definition Number and prevalence





75 + (per 
1000)N Per 1000 
(standardised)
Per cent
All of the five types of medicine 
above
688,006 151.0 (151.6) 40.4 100.2 166.1 331.1
Standardised rates or standard devitions in brackets
See table with 10-year age intervals in Supplementary Material 2 in the electronic supplementary matertial
Conditions marked ‘A’ overlap with other conditions and are thus not counted twice [44]
ATC Anatomical Therapeutic Chemical Classification System, ICD-10 International Statistical Classification of Diseases, 10th Revision
c Complex defined conditions; see reference for further details [44]
**Two-year prevalence
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and private healthcare. Several limitations exist, however, 
one being the obvious fact that being treated for a chronic 
condition is not necessarily the same as being truly ill. There 
may be cases of defensive medicine or patients being treated 
on suspicion of a chronic disease, or even wrong (over-) 
diagnosis.
As found in previous studies, one of the main limitations 
of register studies in general is the opposite, i.e. not being 
able to identify either chronic patients who have not been 
treated or diagnosed at any time or patients with self-treated 
conditions, who consequently are not reported in hospital 
or other registers (i.e. data source limitations, etc.) [44, 
55]. This may lead to under-reporting of some less severe 
chronic conditions, such as asthma, allergies, COPD and 
type 2 diabetes, which are mostly treated in primary care 
where there is no reporting of diagnoses. The same might 
apply for other conditions such as glaucoma, cataracts, age-
related hearing loss, other eye and ear conditions, and less 
severe mental conditions that are untreated, such as mild 
forms of depression or anxiety [44]. Thus, differences in the 
present study are compared with the national self-reported 
prevalence rates for 2013 for 18 broadly defined conditions 
where possible, since they cover a wide range of conditions 
of importance for assessment [6]. In comparison, differences 
and limitations of register-based definitions might be found 
within four of the 18 conditions: osteoarthritis, migraine/
headache, tinnitus and cataracts. These conditions are dis-
cussed in more detail in Supplementary Material 3. All in 
all, these register-based less severe conditions may not be 
sufficiently estimated at this time, which is why register-
based prevalence will be underestimated and should be used 
with caution.
While some estimated conditions show limitations com-
pared to self-reported conditions, most other conditions, 
such as hypertension, rheumatoid arthritis, osteoporosis, 
diabetes, COPD, bronchitis and other lung diseases, can-
cers, heart condition and stroke, all have higher or slightly 
higher register-based than self-reported prevalence [6], as 
well as estimates in line with other studies [7, 10, 33, 55, 
56]. The same applies to mental conditions overall, which 
typically have a lower survey response [57], which could 
explain the lower self-reported prevalence. Added to the fact 
that these estimates are free of self-reported bias, this clearly 
strengthens the reliability of most register-based conditions 
reported, not to mention the enhanced precision of doctor-
reported diagnoses.
However, similar to non-registration issues in commu-
nity-based surveys, misclassification issues also exist in 
register studies as sources of bias. Reasons for this include 
different coding practices between hospitals [30], different 
access to specialists, clinical disagreements, different clini-
cal and administrative practices and interpretation of the 
ICD-10 criteria [58]. However, we do not have evidence 
of systemic misclassification. On the contrary, studies have 
validated reported diagnoses from registers for several psy-
chiatric and somatic conditions, with good overall results 
[55, 59–64]. Nevertheless, the estimates of some complex-
aetiology, ill-defined and debated rheumatoid conditions 
such as fibromyalgia and chronic fatigue syndrome, even 
though common, should be used with caution since they are 
clearly under-reported compared to other studies [58, 65, 
66]. Further discussion and references regarding the validity 
of diagnosis codes in registers can be found elsewhere [44].
In summary, the prevalence of some less severe condi-
tions may be underestimated in register studies [55]. On 
the other hand, community-based self-reported studies may 
underestimate, especially, the more severe conditions due to, 
among other things, non-responders as well as people living 
in institutions or jails, homeless people, and those currently 
in inpatient treatment. Existing studies have already shown 
varying or poor overlap between self-reports and hospital 
reports [67], some concluding that the use of self-reports is 
less reliable in cases of, for example, stroke and ischaemic 
heart disease [68, 69], while severe conditions [67] such as 
cancers cannot reliably be self-diagnosed. Thus, a strength 
of the current study is that moderate or severe conditions 
are estimated more accurately and are naturally free of the 
bias of self-reported conditions. From this perspective, com-
munity-based survey studies contrast with and complement 
register studies [55].
Another strength of the study is that the definitions 
used were evaluated by epidemiologists and clinicians to 
strengthen reliability and provide the best possible repre-
sentation [44]. In addition, the long register time periods are 
noticeable strengths compared to other register studies [7, 
24, 26, 29–31]. Lastly, the use of a complete population of 
4,555,439 people, not to mention the large number of ICD-
10 doctor-reported conditions included, is another strength 
not or rarely seen in other studies.
4.2  Implications
Existing international register studies usually help determine 
current disease burden with implications for, for example, 
the funding of new treatments or others—but usually not 
multiple conditions [70–72].
The prevalence estimates of the current study provide 
unbiased, independent important basic information regard-
ing the burden of disease for use in healthcare planning, as 
well as economic, aetiological and other research for a broad 
range of conditions. As it is based on uniform methodology 
within a single study, it also makes reliable comparisons, 
contrary to most existing studies. In many types of health 
economic studies, such as analyses of cost of illness and the 
budgetary consequences of the introduction of new health 
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technologies, economic calculations may not provide an 
accurate, reliable picture if based on invalid information. 
This comprehensive catalogue of prevalence information 
of nationwide chronic conditions enables comprehensive 
comparisons of chronic diseases for policymakers, patient 
associations and researchers. Thus, it may serve as an off-
the-shelf tool for decision makers and researchers for health 
economic modelling.
4.3  Future Studies
The World Health Organization (WHO) have recommended 
further improvement in data surveillance of chronic condi-
tions worldwide [17]; in addition, other studies have criti-
cised, as well as recommended, methodological improve-
ments [73–76]. Future studies should compare these 
prevalence rates based on actual patient pathways and reg-
istrations of treatment with other methods for estimating 
disease prevalence. Future studies could also focus on the 
development over time of disease burden, including the new-
est register data and analysis of possible trends in diagnosis 
or possible over-diagnosis. Moreover, while there are several 
studies exploring the coherence between self-reported con-
ditions and hospital records, we found no studies assessing 
whether less severe self-reported conditions are more accu-
rately estimated than register-reported conditions. Further 
studies should be carried out to assess whether chosen less 
severe self-reported conditions are estimated accurately, and 
if so, how register and self-reported study designs could best 
complement each other and for which conditions.
5  Conclusions
The current study provides a catalogue of prevalence for 
199 different doctor-reported chronic conditions and groups 
of conditions by gender, based on a complete nationwide 
population sample.
To the best of the authors’ knowledge, this study pro-
vides the most comprehensive descriptive register study of 
the prevalence of treatment of chronic conditions. Hence, 
the overall prevalence rate found is higher than that found in 
several previous studies, indicating that almost two-thirds of 
the entire Danish population aged 16 years or above either 
have a hospital diagnosis and/or are in medical treatment for 
one or more chronic condition.
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